Haverford Trust Company’s Boston Scientific BSX Stock Holding History

Haverford Trust Company’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,212	Closed	-$211K	–	422
2025 Q4	$211K	Buy	+2,212	New	+$217K	﹤0.01%	403
2025 Q3	–	Sell	-2,413	Closed	-$259K	–	400
2025 Q2	$259K	Buy	2,413 +420	+21%	+$42.5K	﹤0.01%	375
2025 Q1	$201K	Buy	+1,993	New	+$201K	﹤0.01%	388

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Haverford Trust Company's BSX Position: Q1 2026 in Review

Haverford Trust Company sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 2,212 shares — an estimated $211K sold.

Haverford Trust Company first reported a position in BSX in Q1 2025 and held it in 3 quarters. The position peaked at $259K in Q2 2025. 1,683 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Haverford Trust Company reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
Haverford Trust Company sold 2,212 Boston Scientific shares in Q1 2026, an estimated $211K.
Haverford Trust Company first reported a position in Boston Scientific in Q1 2025 and held it in 3 quarters.
Haverford Trust Company's Boston Scientific position peaked at $259K in Q2 2025.
1,683 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Haverford Trust Company's 13F filing for Q1 2026, filed 11 May 2026.